Brian Kearney, Pharm.D., of Gilead Sciences Inc., and Robert Guttendorf, Ph.D., of Sequoia Pharmaceuticals discuss encouraging findings from early human trials on a pair of pharmacokinetic enhancers whose utility could potentially extend far beyond protease inhibitor boosting.

Read or listen (22 min.):

• Which CROI 2009 Studies Are Most Likely to Impact Clinical Care? An Interview With Joel Gallant, M.D., M.P.H.
• The Next Stage of HIV Eradication: Finding the Secret Reservoirs
• Ever Upward: "When to Start" Debate Turns to CD4+ Cell Count of 500
• 5% or More of Perinatally HIV-Infected Adolescents May Be Long-Term Nonprogressors, U.S. Study Suggests
• More

The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.

Read or listen (20 min.):

• A Review of Cardiovascular Disease and HIV: Highlights From CROI 2009
• HPV, Anal Cancer and Cervical Cancer: An Update on Pathogenesis, Treatment and Prevention
• Many HIV-Infected Women Do Not Receive Cervical Cancer Screenings Nearly Often Enough, U.S. Study Suggests
• Peripheral Neuropathy Still Common Among HIV-Infected Patients on HAART; Risk May Increase With Age
• More

Prameet Sheth and Anne-Genevieve Marcelin, Pharm.D., Ph.D., offer the latest salvo in the fervent debate triggered by the release of the so-called "Swiss statement" in 2008. These findings suggest that a male patient can experience spontaneous, periodic shedding of HIV into his seminal fluid despite having consistently undetectable viral load levels in his blood.

Read or listen (13 min.):

• Human Trial of Vaginal Microbicide Gel PRO 2000 Finds Some Level of HIV Protection
• HIV Vaccine Development in 2009: Looking Back (and Forward)
• Number of HIV-Infected Women Giving Birth in U.S. Increased 40% From 2000 to 2006, Estimates Show
• Topical PrEP Comparison: Tenofovir Alone May Be as Effective as Tenofovir/FTC, Study Finds
• More